The 2026 Medicine Nobel: A Light Switch for Brain Cells

Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for discoveries concerning light-gated ion channels and optogenetics. The Guardian

The Nobel Assembly at the Karolinska Institute in Stockholm announced the award on 5 October 2026. The announcement was scheduled for 11:30 CEST on Monday, 5 October. It opened a series of 2026 Nobel announcements scheduled for 5 to 12 October. Per Svenningsson is Chair of the Nobel Committee for Physiology or Medicine.

The three laureates will share 12 million Swedish kronor, about £901,500. Deisseroth is affiliated with the Howard Hughes Medical Institute and Stanford University. Hegemann is affiliated with Humboldt University of Berlin. Nagel is affiliated with the University of Würzburg. The Guardian

Hegemann and Nagel discovered the protein channelrhodopsin in the early 2000s. It was found in Chlamydomonas, a single-celled alga that swims towards a light source. When struck by blue light, channelrhodopsin opens and lets charged ions flow into the cell to create an electrical impulse. An ion channel is a gate-like protein that controls that flow. Nobel Prize

Deisseroth introduced the gene for channelrhodopsin into nerve cells from rats. He published work in 2005 showing blue light could trigger nerve signals. Two years later, he made the light-controlled switch work in the brains of living mice. The technique is optogenetics. Like fitting a light switch into selected cells, it uses placement of the microbial gene into chosen cells plus delivery of light, with control limited to certain cell types and timed to milliseconds.

Optogenetics makes it possible to show how nerve cells shape memories, feelings and behaviours in the living brain. Researchers are using it in attempts to restore sight in people with visual impairment.

The 2026 award is the 117th time the Nobel Prize in Physiology or Medicine has been given. Including the 2026 winners, there have been 235 laureates in Physiology or Medicine, of whom 14 have been women.

The broader context here is that the choice rewards tool-building as physiology. Optogenetics did not identify a single disease gene or pathogen. It gave systems neuroscience a causal tool, complementing recording methods with the ability to activate defined neuronal populations in intact circuits and test their contribution to behaviour.

In my view, readers should weigh two trajectories separately. One is continued use of optogenetics as a basic research platform for circuit study in animal models, where specificity and temporal control remain difficult to match. The other is therapeutic translation, where light delivery, stable and safe opsin expression, and long-term tolerability define a different risk and regulatory path. The documented attempts around visual impairment show where that second path is being tested, without treating an experimental intervention as an established treatment.